{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:34:16Z","timestamp":1780515256736,"version":"3.54.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,2,20]],"date-time":"2018-02-20T00:00:00Z","timestamp":1519084800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006314","name":"Biogen Idec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006314","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swiss MS Society"},{"name":"Betty and David Koetser Foundation"},{"name":"Clinical Research Priority Program"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s00415-018-8796-9","type":"journal-article","created":{"date-parts":[[2018,2,23]],"date-time":"2018-02-23T10:41:36Z","timestamp":1519382496000},"page":"1016-1025","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Positive effects of fampridine on cognition, fatigue and depression in patients with multiple sclerosis over 2\u00a0years"],"prefix":"10.1007","volume":"265","author":[{"given":"Sarah D.","family":"Broicher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linard","family":"Filli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Geisseler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Germann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Z\u00f6rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Brugger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Linnebank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,20]]},"reference":[{"key":"8796_CR1","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1007\/s00415-012-6678-0","volume":"260","author":"MP Amato","year":"2012","unstructured":"Amato MP, Amato MP, Langdon D et al (2012) Treatment of cognitive impairment in multiple sclerosis: position paper. J Neurol 260:1452\u20131468","journal-title":"J Neurol"},{"key":"8796_CR2","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/nrneurol.2011.61","volume":"7","author":"RHB Benedict","year":"2011","unstructured":"Benedict RHB, Benedict RHB, Zivadinov R et al (2011) Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nat Rev Neurol 7:332\u2013342","journal-title":"Nat Rev Neurol"},{"key":"8796_CR3","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1212\/WNL.47.6.1457","volume":"47","author":"CT Bever Jr","year":"1996","unstructured":"Bever CT Jr, Anderson PA, Leslie J et al (1996) Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial. Neurology 47:1457\u20131462","journal-title":"Neurology"},{"key":"8796_CR4","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/00019052-200306000-00006","volume":"16","author":"JA Bobholz","year":"2003","unstructured":"Bobholz JA, Rao SM (2003) Cognitive dysfunction in multiple sclerosis: a review of recent developments. Curr Opin Neurol 16:283\u2013288","journal-title":"Curr Opin Neurol"},{"key":"8796_CR5","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1093\/sleep\/33.8.1061","volume":"33","author":"TJ Braley","year":"2010","unstructured":"Braley TJ, Chervin RD (2010) Fatigue in multiple sclerosis: mechanisms, evaluation, and treatment. Sleep 33:1061\u20131067","journal-title":"Sleep"},{"key":"8796_CR6","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/S1474-4422(08)70259-X","volume":"7","author":"ND Chiaravalloti","year":"2008","unstructured":"Chiaravalloti ND, Deluca J (2008) Cognitive impairment in multiple sclerosis. Lancet Neurol 7:1139\u20131151","journal-title":"Lancet Neurol"},{"key":"8796_CR7","first-page":"337","volume":"38","author":"BP Cinar","year":"2017","unstructured":"Cinar BP, Kosehasanogullari G, Yigit P et al (2017) Cognitive dysfunction in patients with multiple sclerosis treated with first-line disease-modifying therapy: a multi-center, controlled study using the BICAMS battery. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol 38:337\u2013342","journal-title":"Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol"},{"key":"8796_CR8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1177\/070674370404900302","volume":"49","author":"A Feinstein","year":"2004","unstructured":"Feinstein A (2004) The neuropsychiatry of multiple sclerosis. Can J Psychiatry (Revue canadienne de psychiatrie) 49:157\u2013163","journal-title":"Can J Psychiatry (Revue canadienne de psychiatrie)"},{"key":"8796_CR9","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1212\/WNL.0000000000003656","volume":"88","author":"L Filli","year":"2017","unstructured":"Filli L, Zorner B, Kapitza S et al (2017) Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis. Neurology 88:832\u2013841","journal-title":"Neurology"},{"key":"8796_CR10","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1080\/13854040802389185","volume":"23","author":"S Goebel","year":"2009","unstructured":"Goebel S, Fischer R, Ferstl R et al (2009) Normative data and psychometric properties for qualitative and quantitative scoring criteria of the five-point test. Clin Neuropsychol 23:675\u2013690","journal-title":"Clin Neuropsychol"},{"key":"8796_CR11","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1177\/1352458514563591","volume":"21","author":"AD Goodman","year":"2015","unstructured":"Goodman AD, Bethoux F, Brown TR et al (2015) Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: results of open-label extensions of two phase 3 clinical trials. Mult Scler 21:1322\u20131331","journal-title":"Mult Scler"},{"key":"8796_CR12","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/ana.22240","volume":"68","author":"AD Goodman","year":"2010","unstructured":"Goodman AD, Brown TR, Edwards KR et al (2010) A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 68:494\u2013502","journal-title":"Ann Neurol"},{"key":"8796_CR13","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/S0140-6736(09)60442-6","volume":"373","author":"AD Goodman","year":"2009","unstructured":"Goodman AD, Brown TR, Krupp LB et al (2009) Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 373:732\u2013738","journal-title":"Lancet"},{"key":"8796_CR14","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1177\/1352458506069538","volume":"13","author":"AD Goodman","year":"2007","unstructured":"Goodman AD, Cohen JA, Cross A et al (2007) Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. Mult Scler 13:357\u2013368","journal-title":"Mult Scler"},{"key":"8796_CR15","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jns.2008.08.025","volume":"276","author":"Y Harel","year":"2009","unstructured":"Harel Y, Appleboim N, Lavie M et al (2009) Single dose of methylphenidate improves cognitive performance in multiple sclerosis patients with impaired attention process. J Neurol Sci 276:38\u201340","journal-title":"J Neurol Sci"},{"key":"8796_CR16","doi-asserted-by":"crossref","unstructured":"Heine M, Van De Port I, Rietberg MB et al (2015) Exercise therapy for fatigue in multiple sclerosis. Cochrane Database Syst Rev 9:CD009956","DOI":"10.1002\/14651858.CD009956.pub2"},{"issue":"14","key":"8796_CR17","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1177\/1352458514533844","volume":"20","author":"H Jensen","year":"2014","unstructured":"Jensen H, Ravnborg M, Mamoei S et al (2014) Changes in cognition, arm function and lower body function after Slow-Release Fampridine treatment. Mult Scler J 20(14):1872\u20131880","journal-title":"Mult Scler J"},{"key":"8796_CR18","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1682\/JRRD.2004.09.0116","volume":"43","author":"SI Judge","year":"2006","unstructured":"Judge SI, Lee JM, Bever CT Jr et al (2006) Voltage-gated potassium channels in multiple sclerosis: overview and new implications for treatment of central nervous system inflammation and degeneration. J Rehabil Res Dev 43:111\u2013122","journal-title":"J Rehabil Res Dev"},{"key":"8796_CR19","doi-asserted-by":"publisher","first-page":"e00559","DOI":"10.1002\/brb3.559","volume":"7","author":"M Korsen","year":"2017","unstructured":"Korsen M, Kunz R, Schminke U et al (2017) Dalfampridine effects on cognition, fatigue, and dexterity. Brain Behav 7:e00559","journal-title":"Brain Behav"},{"key":"8796_CR20","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1212\/WNL.0b013e318218107a","volume":"76","author":"LB Krupp","year":"2011","unstructured":"Krupp LB, Christodoulou C, Melville P et al (2011) Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis. Neurology 76:1500\u20131507","journal-title":"Neurology"},{"key":"8796_CR21","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1212\/WNL.55.7.934","volume":"55","author":"LB Krupp","year":"2000","unstructured":"Krupp LB, Elkins LE (2000) Fatigue and declines in cognitive functioning in multiple sclerosis. Neurology 55:934\u2013939","journal-title":"Neurology"},{"key":"8796_CR22","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s00415-009-0152-7","volume":"256","author":"R Lange","year":"2009","unstructured":"Lange R, Volkmer M, Heesen C et al (2009) Modafinil effects in multiple sclerosis patients with fatigue. J Neurol 256:645\u2013650","journal-title":"J Neurol"},{"key":"8796_CR23","doi-asserted-by":"publisher","first-page":"i29","DOI":"10.1007\/s00415-006-1107-x","volume":"253","author":"E Lensch","year":"2006","unstructured":"Lensch E, Matzke M, Petereit H-F et al (2006) Identification and management of cognitive disorders in multiple sclerosis. J Neurol 253:i29\u2013i31","journal-title":"J Neurol"},{"key":"8796_CR24","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1159\/000442348","volume":"74","author":"E Magnin","year":"2015","unstructured":"Magnin E, Sagawa Y Jr, Chamard L et al (2015) Verbal fluencies and fampridine treatment in multiple sclerosis. Eur Neurol 74:243\u2013250","journal-title":"Eur Neurol"},{"key":"8796_CR25","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/ana.1032","volume":"50","author":"WI Mcdonald","year":"2001","unstructured":"Mcdonald WI, Compston A, Edan G et al (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121\u2013127","journal-title":"Ann Neurol"},{"key":"8796_CR26","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jns.2005.08.022","volume":"245","author":"X Montalban","year":"2006","unstructured":"Montalban X, Rio J (2006) Interferons and cognition. J Neurol Sci 245:137\u2013140","journal-title":"J Neurol Sci"},{"key":"8796_CR27","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.msard.2016.10.011","volume":"11","author":"SA Morrow","year":"2017","unstructured":"Morrow SA, Rosehart H, Johnson AM (2017) The effect of fampridine-SR on cognitive fatigue in a randomized double-blind crossover trial in patients with MS. Mult Scler Relat Disord 11:4\u20139","journal-title":"Mult Scler Relat Disord"},{"key":"8796_CR28","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.clineuro.2015.08.023","volume":"139","author":"K Pavsic","year":"2015","unstructured":"Pavsic K, Pelicon K, Ledinek AH et al (2015) Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients. Clin Neurol Neurosurg 139:35\u201340","journal-title":"Clin Neurol Neurosurg"},{"key":"8796_CR29","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1191\/1352458504ms1051oa","volume":"10","author":"A Romani","year":"2004","unstructured":"Romani A, Bergamaschi R, Candeloro E et al (2004) Fatigue in multiple sclerosis: multidimensional assessment and response to symptomatic treatment. Mult Scler 10:462\u2013468","journal-title":"Mult Scler"},{"key":"8796_CR30","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1177\/135245850100700602","volume":"7","author":"PM Rossini","year":"2001","unstructured":"Rossini PM, Pasqualetti P, Pozzilli C et al (2001) Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Mult Scler 7:354\u2013358","journal-title":"Mult Scler"},{"key":"8796_CR31","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jns.2013.11.011","volume":"337","author":"T Ruck","year":"2014","unstructured":"Ruck T, Bittner S, Simon OJ et al (2014) Long-term effects of dalfampridine in patients with multiple sclerosis. J Neurol Sci 337:18\u201324","journal-title":"J Neurol Sci"},{"key":"8796_CR32","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1212\/WNL.44.9.1701","volume":"44","author":"RC Smits","year":"1994","unstructured":"Smits RC, Emmen HH, Bertelsmann FW et al (1994) The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study. Neurology 44:1701\u20131705","journal-title":"Neurology"},{"key":"8796_CR33","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1177\/1352458511404585","volume":"17","author":"JF Sumowski","year":"2011","unstructured":"Sumowski JF, Chiaravalloti N, Erlanger D et al (2011) L-amphetamine improves memory in MS patients with objective memory impairment. Mult Scler 17:1141\u20131145","journal-title":"Mult Scler"},{"key":"8796_CR34","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/WNF.0000000000000130","volume":"39","author":"EW Triche","year":"2016","unstructured":"Triche EW, Ruiz JA, Olson KM et al (2016) Changes in cognitive processing speed, mood, and fatigue in an observational study of persons with multiple sclerosis treated with dalfampridine-ER. Clin Neuropharmacol 39:73\u201380","journal-title":"Clin Neuropharmacol"},{"key":"8796_CR35","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jpsychores.2016.09.002","volume":"90","author":"LE Akker Van Den","year":"2016","unstructured":"Van Den Akker LE, Beckerman H, Collette EH et al (2016) Effectiveness of cognitive behavioral therapy for the treatment of fatigue in patients with multiple sclerosis: a systematic review and meta-analysis. J Psychosom Res 90:33\u201342","journal-title":"J Psychosom Res"},{"key":"8796_CR36","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1177\/1352458515622695","volume":"22","author":"B Zorner","year":"2016","unstructured":"Zorner B, Filli L, Reuter K et al (2016) Prolonged-release fampridine in multiple sclerosis: improved ambulation effected by changes in walking pattern. Mult Scler 22:1463\u20131475","journal-title":"Mult Scler"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-018-8796-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-018-8796-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-018-8796-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,19]],"date-time":"2019-02-19T19:13:54Z","timestamp":1550603634000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-018-8796-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,20]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["8796"],"URL":"https:\/\/doi.org\/10.1007\/s00415-018-8796-9","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,20]]},"assertion":[{"value":"29 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Z\u00f6rner received honoraria, travel grants and funding from Biogen. Prof. Linnebank received honoraria, travel grants and funding from Biogen. He is a consultant to Biogen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was approved by the cantonal ethics committee Zurich, Switzerland, and the regulatory agency for medicines (Swissmedic), and was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standard"}}]}}